Boosted by Celgene's cash, BMS bounces back after mega-merge...

Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.

BMS, BioMotiv alliance generates biopharma company Anteros

FDA grants fast review to BMS' first-line lung cancer combo

Bristol-Myers Squibb has finally made its bid for a slice of the lucrative first-line lung non-small cell lung cancer (NSCLC) market, after the FDA agreed to quickly review trial results fr

BMS files first drug from triple bet with Celgene shareholde...

Bristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” with former investors in Celgene that could pay out billions if they all successfully make i

BMS preps filings for leukaemia maintenance therapy CC-486

Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will